Kornimate/medical-research-clean huggingface dataset:
remote dielectric sensing (reds) assisted diuresis in acute decompensated heart failure

Conditions: Heart Failure; With Decompensation

Summary: this study evaluates the use of a wearable vest capable of non-invasively measuring lung fluid content in hospitalized patients with heart failure

inpatient management of acute decompensated heart failure centers around the efficient relief of congestion with iv diuretics and vasoactive agents. for the majority of patients, non-invasive, clinical bedside tools such as jugular venous pressure, pulmonary auscultation and daily weights are used to estimate cardiac filling pressures and guide diuresis. however, these methods are subject to significant inter-observer variability and can be unreliable for various reasons. furthermore, recent studies have shown that overt signs of clinical congestion correlate poorly with hemodynamic congestion assessed by invasive means. remote dielectric sensing is a novel technology that enables the non-invasive assessment of lung fluid content using a wearable vest. reds measurements have been shown to correlate with fluid status in hospitalized hf patients and have been used to remotely monitor ambulatory hf patients for signs of pre-clinical hemodynamic congestion. in this prospective, randomized study, we will assess the utility of reds guided diuresis in hospitalized patients with acute decompensated heart failure. all patients will receive daily reds measurements, but only treating physicians in the intervention group will be able to use these values to guide treatment.

Eligibility criteria:
inclusion criteria: * patients hospitalized for acute decompensated heart failure requiring treatment with intravenous diuretics and/or iv vasoactive drugs * patient has signed informed consent and has authorized use and disclosed health information * patient is at least 18 years of age * patient physically suitable for reds measurement * gfr\>25 * initial reds measurement \>35% exclusion criteria: * patient characteristics excluded from approved use of reds system: height less than 155cm or greater than 190cm, bmi \ 39, chest circumference \ 115cm , or flail chest * evidence of focal lung lesions on history, physical exam or chest x-ray, including history of pulmonary embolism, active pneumonia, or known lung nodule * chronic renal failure (gfr\<25) * prior cardiac surgery within 2 months of index admission * patient has a ventricular assist device or has had a cardiac transplantation * patients in cardiogenic shock at admission requiring inotropic support * congenital heart malformations or intra-thoracic mass that would affect right-lung anatomy (e.g dextrocardia, lung carcinoma, or pacemaker box in the right chest)
pd-1 antibody for reactive ebv after bmt

Conditions: PD-1; EBV Infection; Transplant

Summary: pd-1 antibody for reactivation of ebv after transplantation in patients with caebv/ebv-hlh

transplantaion is recongnized as a cure for caebv and ebv associated hlh，however, many patients undergo the reactivation of ebv after transpaltion, patiens may at high risk for recurrence of the disease. pd-1 is a promising therapy to solve this problem. the present study was a one-arm clinical study, the main subject is to evaluate the effect of pd-1 antibody on the clearance of ebv

Eligibility criteria:
inclusion criteria: 1. meet hemophagocytic lymphohistiocytosis (hlh)-04 diagnostic criteria; ebv-dna in peripheral blood or eber in tissue were positive, patients were diagnosed with ebv associated hlh (ebv-hlh). chronic active ebv infection (caebv) was diagnosed by who criteria. 2. undergo allo-hct, have achieved full chimerism 3. age \>18 years old, gender is not limited. 4. after transplantation, ebv was reactivated and ebv-dna was positive in blood 5. no secondary graft failure. (after grafted, anc \<0.5\*10\^9/l,plt \<10\*10\^9/l) 6. no uncontrollable infection 7. withdraw immunosuppressor, no graft-versus-host disease was observed. 8. before the start of the study, aminopherase (alt/ast) and total bilirubin were normal. serum creatinine ≤ 1.5 times the upper limit of normal (uln); no thyroid dysfunction. the left ventricular ejection fraction (lvef) was normal. 9. informed consent. exclusion criteria: 1. allergic to toripalimab 2. serious immunoreaction: myocardial damage, hepatitis, pneumonia 3. central nervous system symptoms 4. serious mental illness; 5. active bleeding of the internal organs 6. pancreatitis history. patients unable to comply during the trial and/or follow-up phase; 7. participate in other clinical research at the same time.
the efficacy of peritubal analgesic infiltration in postoperative pain following percutaneous nephrolithotomy

Conditions: Renal Stone

Summary: the investigators aim to investigate the effect of peritubal local anesthetic infiltration on pain scores and analgesic consumption in patients who underwent percutaneous nephrolithotomy.

the investigators aim to investigate the effect of peritubal local anesthetic on pain scores and analgesic consumption in patients who underwent percutaneous nephrolithotomy. patients aged between 18 and 65 years with renal stone \>2 cm will be included in this study .the patients will be divided into two groups. in group a , the drug will be infiltrated to the renal capsule, perinephric fat, muscles, subcutaneous tissue, and skin under fluoroscopy with 0.25 percent bupivacaine. this is a widely-used procedure by surgeons in the world. in group b, no anesthetic will be infiltrated after the end of the procedure.

Eligibility criteria:
inclusion criteria: * 18-70 years of age * body mass index \<35, * renal stone size \>2.0 cm. exclusion criteria: * patients having supra-costal puncture. * excessive intraoperative bleeding. * renal stones requiring more than a single puncture. * surgical procedure extending more than 3 hours. * urinary tract infection. * severe cardiopulmonary disease. * abnormal renal function tests. * allergy to local anesthetics.
acute effects of fats on satiety and energy needs

Conditions: Obesity

Summary: the purpose of this study is to assess the acute effect of dietary fat on satiety and energy metabolism.

the influences of specific dietary fat sources on satiety, appetite and energy utilization remains unclear; evidence is lacking on whether responses vary according to acute intake. the researchers will use a controlled setting to determine whether the source of dietary fat is related to perceived satiety, satiety hormone responses, and energy expenditure by conducting experiments to evaluate short term (acute) effects.

Eligibility criteria:
inclusion criteria: * body mass index between 18.0-34.9 kg/m2 * free of major diagnosed, untreated medical conditions * controlled hypertension * non-smoking or use of other tobacco products, including e-cigarettes * not taking steroid-based medications * not planning to or currently attempting to gain or lose weight * willing to comply with study demands * use of oral contraceptives * low intake of long chain omega 3 fatty acids exclusion criteria: * diagnosed eating disorders * diabetes (blood sugar ≥ 126 mg/dl) * hypertension (systolic ≥ 160 mmhg or diastolic \> 100 mmhg) * diagnosed cardiovascular, pulmonary, skeletal and metabolic disease * currently pregnant or planning to become pregnant, or lactating * taking medications known to affect appetite, blood lipids, body composition, body weight, or food intake (appetite control drugs, steroids, antidepressants)

Keywords: energy expenditure appetite satiety
evaluation of the performance of a robotic flexible ureteroscopy (ily) in laser treatment of nephrolithiasis

Conditions: Lithiasis, Urinary

Summary: in this pilot study, we wish to evaluate the performance of a robotic flexible ureteorscopy (ily) in the treatment of nephrolithiasis in the superior excretory system


Eligibility criteria:
inclusion criteria: * the patient must have given their free and informed consent and signed the consent form * the patient must be a member or beneficiary of a health insurance plan * the patient is at least 18 years old * the patient has a single kidney stone in the calyx or the pelvis between 5 and 15mm something to do with a jj probe * patient has an indication for in situ lithotripsy by supply ureteroscopy exclusion criteria: * the subject is participating in an interventional study, or is in a period of exclusion determined by a previous study * the patient is under safeguard of justice or state guardianship * the subject refuses to sign the consent * it is impossible to give the subject informed information * the patient is pregnant or breastfeeding * patient treated with anticoagulants * documented untreated urinary infection within the previous 48 hours
development and clinical application of two new genetic deafness gene diagnostic kit

Conditions: Waardenburg Syndrome; Large Vestibular Aqueduct Syndrome

Summary: the purpose of this study is to develop and applicate two new genetic deafness gene diagnostic kit for waardenburg syndrome and large vestibular aquduct syndrome.

1. for the pathogenic gene of waardenburg syndrome and large vestibular aqueduct syndrome, based on the second-generation sequencing technology, the investigators develop multiplex pcr system for these two hereditary deafness gene diagnostic kit. 2. using cnvplex high-throughput gene copy number detection technology to analyse warrdenburg syndrome pathologic gene. cnvs analysis for warrdenburg deafness syndrome develop special testing system / kit achieve snp / cnvs detected simultaneously, as a supplementary means of genetic testing in clinical deafness.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of waardenburg syndrome * clinical diagnosis of large vestibular aqueduct syndrome exclusion criteria: * could not be able to exsanguinate

Keywords: waardenburg syndrome large vestibular aqueduct syndrome diagnosis copy number variation multiplex polymerase chain reaction
a study to examine the safety, pharmacokinetics and pharmacodynamics of amg 623 in subjects with systemic lupus erythematosus

Conditions: Systemic Lupus Erythematosus

Summary: this study is to evaluate the safety of amg 623 in subjects with systemic lupus erythematosus. all subjects will receive 4 weekly doses of study drug over a 3 week period, and then will be followed for an additional 28 weeks, for total study duration of 31 weeks.


Eligibility criteria:
inclusion criteria: * men and women between the ages of 18 and 65 years old * diagnosis of sle * stable disease; defined as no change in sle therapy within the previous 30 days. up to 5 mg/day incremental changes of prednisone therapy is allowed during the 30 days prior to randomization * sle disease duration of at least 1 year, as diagnosed by a physician exclusion criteria: * current renal disease * signs or symptoms of viral or bacterial infection within 30 days of enrollment * any disorder (including psychiatric), condition or clinically significant disease (other than a diagnosis of sle) that would interfere the study evaluation, completion and/or procedures per the investigator's discretion * administration of more than 10 mg/day prednison (or equivalent) in the 30 days prior to randomization
aerobic and strength training with caloric restriction on insulin resistance in obese premenopausal women

Conditions: Insulin Resistance Syndrome

Summary: a total of 42 premenopausal women diagnosed clinically as having insulin resistance. their ages ranged from 35 to 45 years old; their body mass index was \>30 kg/m2 and they were obese women complained of insulin resistance and non diabetic or cardiovascular disease, were randomly assigned to group a participated in aerobic \& resistive exercise program, and group b participated in aerobic exercise and followed prescribed diet restriction program. both of the groups (a\&b) followed the treatment program 3 times per weeks for 8 weeks. assessment of the fasting glucose, fasting insulin, and homa test of insulin resistance were measured for all subjects in both groups (a and b) was carried out before and after the end of the treatment program

forty two obese premenopausal women diagnosed as having insulin resistance were participated in this study. they were selected randomly from the out patient clinic of obstetrics at kasr el ainy university hospital, faculty of medicine, cairo university. their age ranged from 35 - 45years, their body mass (bmi) were\>30kg/m2. exclusion criteria of the study were as follows: patients having diabetic or cardiovascular disease, patients with life threatening disorders as renal failure and myocardial infarction, patients with active malignancy and patients with severe hemorrhage, hyperthyroidism, acute viral diseases and mental disorders. participants were assigned randomly used sealed envelope into two groups (a\&b) equally in number. group (a): (combined resistive and aerobic exercise group) consisted of 20 women were participated in aerobic \& resistive exercise program plus diet restriction, 3 times per weeks for 8 weeks. group (b): consisted of 20 women were participated in aerobic exercise plus diet restriction 3 times per weeks for 8 weeks.

Eligibility criteria:
inclusion criteria: * their age ranged from 35 - 45years. * their body mass (bmi) were\>30kg/m2. exclusion criteria: * patients having diabetic or cardiovascular disease. * patients with life threatening disorders as renal failure and myocardial infarction * patients with active malignancy. * patients with severe hemorrhage * hyperthyroidism.

Keywords: resistive exercises aerobic exercises diet insulin resistance premenopausal
cerebrospinal fluid repository

Conditions: Amyotrophic Lateral Sclerosis; Cerebrospinal Fluid; Neurodegenerative Disease; Motor Neuron Disease

Summary: the purpose of a csf repository is to collect samples of spinal fluid from controls and patients with neurologic disorders including but not exclusively als, dementia, crps, neuropathies, and other neuromuscular diseases. this csf repository will allow the use of csf in biochemical studies of various neurologic diseases. it would also provide a supply of the necessary normal and disease control patients. csf would be obtained from patients who are undergoing spinal taps for other reasons including diagnosis, treatment, or participation in clinical trials. we are proposing to collect an additional \< 3 ml of csf from a lumbar puncture that is already being performed for diagnostic or therapeutic reasons, in order to store it in our laboratory for use in future research studies. no lumbar punctures will be initiated specifically for this protocol.

the only specific procedures unique to this protocol is the collection of an additional 3ml or less of cerebrospinal fluid from a lumbar puncture already being performed and the collection of clinical information from the patients medical records. lumbar puncture may be either a research procedure or a standard of care procedure, depending upon the reason for initiating the puncture. we will aliquot the additional fluid into a separate storage container and it will be maintained in the laboratory of dr. heiman-patterson at -70 degrees. clinical information including age, medical and neurological history, laboratory data, and pathologic information where indicated will be abstracted from the patient chart. all specimens and corresponding clinical information will be labeled with an identification number and sorted by diagnosis. there will be no patient identifying information kept with the specimens. the csf sample may be used for studies performed by researchers at drexel university college of medicine or shared with collaborators. the csf sample provided will only be used for projects that have approval by the irb, but subjects will not be notified each time it is used for a study. if csf sample is still available, consent can be withdrawn at any time by writing a letter to dr. heiman-patterson requesting the withdrawal of the sample. researchers will request control and disease specific samples to use in various research studies. there are no dna studies.

Eligibility criteria:
inclusion criteria: * any person undergoing a diagnostic lumbar puncture with a neurologic illness * any person undergoing a lumbar puncture as part of anesthesia * any person who is undergoing a lumbar puncture for other research purposes such as clinical trials and who has already consented to the lumbar puncture for that purpose. exclusion criteria: * anyone who is not undergoing a lumbar puncture for other reasons

Keywords: amyotrophic lateral sclerosis cerebrospinal fluid neurodegenerative disease motor neuron disease autonomic nervous system neurodegenerative diseases movement disorders
the effect of early radiofrequency turbinate reduction on persistent allergic rhinitis

Conditions: Allergic Rhinitis

Summary: the primary outcome of this study is to evaluate the effect of radiofrequency turbinate reduction as an initial treatment on clinical improvement (using visual analogue scale based on total nasal symptoms score, peak nasal inspiratory flow, and turbinate size using imagej), inflammatory mediators (elisa from nasal secretions was performed to measure ecp, il-5, and hsp-70), and remodeling markers (through nasal biopsy followed by immunohistochemistry examination to evaluate mmp-9, timp-1, and pai-1). in this randomized, controlled trial, 32 patients with moderate-severe persistent ar were randomly divided into 2 groups. intervention group received radiofrequency turbinate reduction followed by intranasal steroid and antihistamine h-1(ah-1), control group received intranasal steroid and ah-1. both groups were evaluated for clinical improvement in week 4 and 8 after treatment, inflammatory mediators and remodeling markers in week 4 after treatment.

the study compares 2 groups of moderate-severe persistent allergic rhinitis (ar). the intervention group receives radiofrequency turbinate reduction followed by pharmacology treatment (intranasal steroid and ah-1) while the control group receives only pharmacology treatment. diagnosis of ar will be made through clinical history, physical examination, and skin puncture test. patients aged 18-55 years old with moderate-severe persistent ar who come to the outpatient clinic and have signed the informed consent form will be included in this study. moderate-severe ar is defined as having ar symptoms for more than 4 days in a week and more than 4 weeks, with symptoms affecting the subjects' quality of life. patients will be assigned to two groups of treatment randomly with a single blind block randomization.

Eligibility criteria:
inclusion criteria: * subjects with moderate-severe persistent allergic rhinitis who come to the outpatient clinic and has signed the informed consent form. exclusion criteria: * smokers * septum deviation in nasal valve without septal swell body * unilateral inferior turbinate hypertrophy caused by septum deviation * pregnant * severe systemic disease * acute rhinitis or rhinosinusitis within 6 weeks before the study period * nasal polyp * nasal or paranasal tumor * subjects who had received other methods of inferior turbinate reduction, posterior nasal neurectomy, functional endoscopic sinus surgery, caldwell luc * subjects who had received topical steroid for 4 weeks before the study period * coagulation disorder

Keywords: allergic histamine antagonist radiofrequency turbinate reduction rhinitis steroid
study of a simplified geriatric evaluation performed by oncologists prior to cancer treatment by radiotherapy or chemotherapy in subjects aged 70 years or older with inoperable squamous cell cancer of the head and neck

Conditions: Inoperable Squamous Cell Cancer of the Head and Neck

Summary: use by oncologists of validated geriatric assessment tools: g8 screening test and certain tests for thorough geriatric evaluation


Eligibility criteria:
inclusion criteria: * subject aged 70 or over * carrier of squamous cell carcinoma of the head and neck, locally advanced undergoing treatment by radiotherapy or metastatic / recurrence not accessible to treatment curative locoregional under treatment with chemotherapy. * patient likely to be eligible for elan-rt or elan-fit or elan-unfit trials. * patients affiliated to a social security scheme exclusion criteria: * person deprived of liberty or under guardianship, * presence of a neuro-psychological condition, family, social, or geographical, which may hinder the smooth running of the study. * patient expressing opposition to participation in this study
dna analysis of tumor tissue from patients with acute myeloid leukemia

Conditions: Leukemia

Summary: rationale: studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. it may also help doctors predict how well patients respond to treatment. purpose: this laboratory study is looking at tissue samples from patients with acute myeloid leukemia.

objectives: primary * determine gene expression, genome integrity, cytosine methylation, and chromatin structure in patients with normal cytogenetics leukemia (ncl) acute myeloid leukemia. * determine whether ncl can be deconstructed into specific disease entities by analysis of the integrated genomic and epigenomic datasets using supervised and unsupervised methods in these patients. * identify the gene pathways that define ncl subtypes and molecular targets for validation in preclinical and clinical trials for these patients. * determine whether integrated analysis provides markers of prognostic and therapeutic response that accurately predicts clinical outcome and can be used to select patients for risk-stratified therapeutic trials. outline: this is a pilot, multicenter study. samples are analyzed to assess array comparative genomic hybridization using polymerase chain reaction (pcr) and fluorescent in situ hybridization; chromatin immunoprecipitations (chip) using pcr; hpa ii tiny fragment enrichment by ligation-mediated pcr (help) using dna methylation analysis; and gene expression profiling. projected accrual: a total of 32 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * diagnosis of acute myeloid leukemia * enrolled on clinical trial ecog-e1900 patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: adult acute myeloid leukemia in remission recurrent adult acute myeloid leukemia untreated adult acute myeloid leukemia adult acute myeloid leukemia with 11q23 (mll) abnormalities adult acute myeloid leukemia with inv(16)(p13;q22) adult acute myeloid leukemia with t(15;17)(q22;q12) adult acute myeloid leukemia with t(16;16)(p13;q22) adult acute myeloid leukemia with t(8;21)(q22;q22)
ac-ole-01-va tolerability study in healthy participants under different dosing conditions

Conditions: Alzheimer Disease

Summary: this is an open-label, 3-arm study to compare tolerability of three different titration and dosing schedules of the ac-ole-01-va formulation of tricaprilin. following a screening of up to 28 days, eligible participants will be initially randomised to one of 2 arms (arm 1 or arm 2). arms 1 and 2 will be completed in advance of arm 3 with all subsequent participants allocated to arm 3.


Eligibility criteria:
inclusion criteria: * participants who are overtly healthy (in the opinion of the investigator) as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring. * body weight ≥45 kg and body mass index (bmi) within the range 18.0 - 32.0 kg/m2 (inclusive). exclusion criteria: * history of, or current gastrointestinal (gi) conditions constituting a risk when taking the study treatment; or interfering with the interpretation of data, based on the investigator's judgement. * participants on a ketogenic diet, low-fat diet or actively using medium chain triglycerides, ketone esters, or other ketogenic products within 3 months prior to screening.